34 results on '"Bruin, Gerard"'
Search Results
2. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women
3. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans
4. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
5. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis: 1264
6. Secukinumab, a novel anti–IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays: 1320
7. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*.
8. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
9. Thoracoabdominal Aortic Aneurysm Repair: A Prospective Cohort Study of 121 Cases
10. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnʼs disease: unexpected results of a randomised, double-blind placebo-controlled trial
11. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial.
12. A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications
13. Use of a Microplate Scintillation Counter as a Radioactivity Detector for Miniaturized Separation Techniques in Drug Metabolism
14. Integrated capillary electrophorosis on flexible silicone microdevices: analysis of DNA restriction fragments and detection of single DNA molecules on microchips
15. Hologram-based refractive index detector for capillary electrophoresis: separation of metal ions
16. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
17. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
18. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.
19. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
20. Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis.
21. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.
22. Immunoaffinity screening with capillary electrochromatography.
23. Recent developments in electrokinetically driven analysis on microfabricated devices.
24. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE.
25. 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis.
26. 25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year.
27. Fritless capillary electrochromatography.
28. Preconcentration and separation of antisense oligonucleotides by on-column isotachophoresis and capillary electrophoresis in polymer-filled capillaries.
29. Integrated chip-based capillary electrophoresis.
30. Reply.
31. Theoretical and experimental aspects of indirect detection in capillary electrophoresis
32. Stability measurements of antisense oligonucleotides by capillary gel electrophoresis
33. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
34. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.